ProMIS Neurosciences Inc. (PMN)vsVertex Pharmaceuticals Inc (VRTX)
PMN
ProMIS Neurosciences Inc.
$17.43
-1.91%
HEALTHCARE · Cap: $37.88M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 158747254% more annual revenue ($12.00B vs $7,560). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
PMN
Avoid21
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for PMN.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : PMN
PMN has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : PMN
The primary concerns for PMN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
PMN profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.32 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 21/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ProMIS Neurosciences Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
ProMIS Neurosciences Inc. is an innovative biotechnology company focused on developing transformative therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the firm identifies and targets misfolded proteins linked to these debilitating conditions, delivering the potential for groundbreaking treatments with enhanced safety profiles. With a diverse pipeline of drug candidates progressing through various stages of development, ProMIS stands at the forefront of neurotherapeutic advancements, poised to address significant unmet medical needs and exert a meaningful impact within the biopharmaceutical landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?